Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORM for Oropharyngeal Candidiasis
NCT06120816Phase 1Completed
- Sponsor
- SaNOtize
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nitric oxide in oropharyngeal candidiasis (OPC), sponsored by SaNOtize. Primary endpoint: Tolerability of NORM at 21 days. Started Jan 2024; status: completed.
02
Drugs
nitric oxide
03
Conditions
oropharyngeal candidiasis (OPC)
Beyond the preview
Go deeper on NCT06120816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120816.